Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

CIR Expert Panel To Prioritize Cannabidiol Review In 2024 At FDA’s Request

Mar 14 2023

• By Lauren Nardella

Conceptual image of CBD legalization and use.

Related Content

US FDA ‘Punt’ On Hemp Rulemaking Frustrates, Confuses Supplement Industry

Jan 27 2023

Wildflower Rep Before FDA Cannabis Panel: CBD’s Functional Purpose In Beauty Products? Er …

May 31 2019

FDA’s Cannabidiol Crackdown: What Do Warning Letters Say About CBD In Cosmetics?

Dec 05 2019

FDA Proposes Priorities For Cosmetic Ingredient Review: Mica, Probiotics, CBD

Apr 18 2019

US FDA’s Stance On CBD In Cosmetics Hasn’t Changed, And Neither Have Marketing Challenges

Oct 05 2020

Additional Topics

United States Cosmetic Ingredients Cannabidiol CBD Safety Cosmetics Consumer

More from Ingredients & Safety

More from HBW Insight

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window